Literature DB >> 3763367

Specimen handling in an HPLC determination of phenylbutazone and its major metabolites in plasma, avoiding degradation of the compounds.

M J Franssen, Y Tan, I Freij, C A Van Ginneken, F W Gribnau.   

Abstract

A problem usually not taken into account when a quantitative HPLC method for phenylbutazone is developed is the degradation of this drug and its metabolites not only upon storage, but also on extraction under acidic conditions, especially when the temperature is raised. Moreover, the degradation products in the chromatograms may interfere with the determination of gammahydroxyphenylbutazone. In our newly developed HPLC method, using feprazone as an internal standard, extreme care is taken to avoid degradation of the compounds during the extraction procedure. In view of the present results it is concluded that previously published data on phenylbutazone, oxyphenbutazone and gammahydroxyphenylbutazone levels should be considered with reserve.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3763367     DOI: 10.1007/bf01957783

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  22 in total

1.  Disposition and oxidative metabolism of phenylbutazone in man.

Authors:  J Aarbakke; O M Bakke; E J Milde; D S Davies
Journal:  Eur J Clin Pharmacol       Date:  1977       Impact factor: 2.953

2.  Effect of phenylbutazone breakdown products on drug metabolism assay.

Authors:  G D Bellward; R G Morgan; V H Beaulne; A G Mitchell
Journal:  J Pharm Pharmacol       Date:  1972-04       Impact factor: 3.765

3.  Oxyphenbutazone and phenylbutazone determination in plasma and urine by GLC.

Authors:  R B Bruce; W R Maynard; L K Dunning
Journal:  J Pharm Sci       Date:  1974-03       Impact factor: 3.534

4.  Analysis of phenylbutazone in plasma by high-speed liquid chromatography.

Authors:  N J Pound; I J McGilveray; R W Sears
Journal:  J Chromatogr       Date:  1974-02-13

5.  GLC determination of plasma concentration of phenylbutazone and its metabolite oxyphenbutazone.

Authors:  K K Midha; I J McGilveray; C Charette
Journal:  J Pharm Sci       Date:  1974-08       Impact factor: 3.534

6.  Ultraviolet spectrophotometric determination of phenylbutazone in biologic specimens.

Authors:  J E Wallace
Journal:  J Pharm Sci       Date:  1968-12       Impact factor: 3.534

7.  Reversed-phase high-performance liquid chromatography of phenylbutazone in body fluids.

Authors:  M Alvinerie
Journal:  J Chromatogr       Date:  1980-01-11

8.  An improved HPLC assay for monitoring phenylbutazone and its two major oxidised metabolites in plasma.

Authors:  L Aarons; C Higham
Journal:  Clin Chim Acta       Date:  1980-08-19       Impact factor: 3.786

9.  Gas chromatographic determination of butazolidin (phenylbutazone) in biological fluids.

Authors:  R D Budd
Journal:  J Chromatogr       Date:  1982-07-16

10.  Metabolism of phenylbutazone in man.

Authors:  W Dieterle; J W Faigle; F Früh; H Mory; W Theoblad; K O Alt; W J Richter
Journal:  Arzneimittelforschung       Date:  1976-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.